New study prepares anthrax drug for bioterror attack
NCT ID NCT02177721
First seen Feb 06, 2026 · Last updated May 25, 2026 · Updated 13 times
Summary
This study looks at how well the drug raxibacumab works and how safe it is for people who get sick from breathing in anthrax spores during a mass event, like a bioterrorist attack. Researchers will collect information from up to 100 patients of all ages who receive the drug as part of their care. The goal is to learn more about survival and recovery to improve treatment in future emergencies.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for INFECTIONS, BACTERIAL are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.